- Home
- OSW vs MESO Comparison
OSW vs MESO Comparison
Compare OSW & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSW
- MESO
- Stock Information
- Founded
- OSW N/A
- MESO 2004
- Country
- OSW Bahamas
- MESO Australia
- Employees
- OSW N/A
- MESO N/A
- Industry
- OSW Hotels/Resorts
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OSW Consumer Discretionary
- MESO Health Care
- Exchange
- OSW Nasdaq
- MESO Nasdaq
- Market Cap
- OSW 2.0B
- MESO 2.0B
- IPO Year
- OSW N/A
- MESO N/A
- Fundamental
- Price
- OSW $20.21
- MESO $18.04
- Analyst Decision
- OSW Strong Buy
- MESO Buy
- Analyst Count
- OSW 4
- MESO 4
- Target Price
- OSW $20.75
- MESO $13.50
- AVG Volume (30 Days)
- OSW 470.2K
- MESO 828.2K
- Earning Date
- OSW 02-26-2025
- MESO 02-28-2025
- Dividend Yield
- OSW 0.40%
- MESO N/A
- EPS Growth
- OSW 2284.58
- MESO N/A
- EPS
- OSW 0.50
- MESO N/A
- Revenue
- OSW $872,619,000.00
- MESO $5,902,000.00
- Revenue This Year
- OSW $13.42
- MESO $65.99
- Revenue Next Year
- OSW $8.62
- MESO $425.77
- P/E Ratio
- OSW $40.79
- MESO N/A
- Revenue Growth
- OSW 13.60
- MESO N/A
- 52 Week Low
- OSW $11.98
- MESO $1.72
- 52 Week High
- OSW $20.57
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- OSW 62.46
- MESO 59.20
- Support Level
- OSW $18.48
- MESO $15.92
- Resistance Level
- OSW $19.66
- MESO $17.67
- Average True Range (ATR)
- OSW 0.50
- MESO 1.38
- MACD
- OSW 0.04
- MESO -0.37
- Stochastic Oscillator
- OSW 88.72
- MESO 37.14
About OSW OneSpaWorld Holdings Limited
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts worldwide. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.